Showing results (161-170 of 179) with videos related to
Sort By:
Pageof 18
The American Journal of Pathology|September 11, 2017
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene NetworksRyusuke Murakami, Noriomi Matsumura, J B Brown, et al.Journal of Gynecologic Oncology|July 1, 2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trialShin Nishio, Tadaaki Nishikawa, Masahiko Mori, et al.International Journal of Clinical Oncology|January 8, 2025
Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcomaAzusa Sakurai, Ken Yamaguchi, Kentaro Ishida, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJunzo Hamanishi, Masaki Mandai, Takafumi Ikeda, et al.Cancer Science|May 24, 2026
Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian CancerKatsutoshi Oda, Daisuke Shintani, Akira Nishijima, et al.International Journal of Clinical Oncology|August 26, 2024
Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancersAtsushi Yamada, Yukari Doi, Sachiko Minamiguchi, et al.Molecular Cancer Therapeutics|March 12, 2026
A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinomaShunsuke Kawahara, Mana Taki, Junzo Hamanishi, et al.Abdominal Radiology (New York)|April 10, 2025
Differentiating uterine adenosarcoma from endometrial polyps: MRI imaging featuresKumi Harada, Yasuhisa Kurata, Yuki Himoto, et al.Carcinogenesis|March 30, 2022
Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cellsYuka Mise, Junzo Hamanishi, Takiko Daikoku, et al.The Journal of Clinical Investigation|January 17, 2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regressionHeng Lin, Shuang Wei, Elaine M Hurt, et al.Pageof 18